Formulation and Specifications: Tablets: 5 mg
Indications: For patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one prior systemic chemotherapy.
Rational dosing points:
1. Adults are recommended to take 30 mg per dose, twice a week, no less than 3 days between doses (e.g., Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), 30 minutes after breakfast. If the disease has not progressed or no intolerable adverse reactions have occurred, continuous dosing is recommended.
2. Dose adjustment: Suspend the drug in case of grade 3 or 4 neutropenia (neutrophil count <1×109/L), thrombocytopenia (platelet count <50×109/L), or anemia (hemoglobin reduced to <80g/L). Treatment may be continued when absolute neutrophil values recover to ≥1.5×109/L, platelets recover to ≥75×109/L, and hemoglobin recover to ≥90g/L, as confirmed by two consecutive examinations. If the previous adverse reaction is grade 3, the original dose or the dose should be reduced to 20mg/dose when resuming the drug; if the previous adverse reaction is grade 4, the dose should be reduced to 20mg/dose when resuming the drug.
3. Common adverse reactions include: hematological adverse reactions, including decreased platelet count, decreased white blood cell or neutrophil count, decreased hemoglobin; systemic adverse reactions, including malaise and fever; gastrointestinal adverse reactions, including diarrhea, nausea and vomiting; metabolic and nutritional system adverse reactions, including decreased appetite, hypokalemia and hypocalcemia; as well as dizziness and rash; very few patients with ECG will Prolonged QTc interval.
4. Contraindicated in female patients during pregnancy and in patients with severe cardiac insufficiency (NYHA class IV cardiac insufficiency).